|
PCA3Plus® detects PCA3, a specific gene that is highly expressed in prostate cancer. No other human tissues express PCA3.
“We are pleased to be the first to provide the innovative PCA3Plus® test for men at risk for prostate cancer. This test is the second generation of the hugely successful uPM3™ test, the first genetic test for prostate cancer risk available exclusively by Bostwick Laboratories® since 2004. PCA3Plus® uses technology that provides even greater reproducibility than uPM3™,” said David G. Bostwick, MD, MBA, Chief Executive Officer and Chief Medical Officer.
PCA3Plus® tests for prostate cancer cells that are shed into the urine. The urine sample is sent to Bostwick Laboratories® to be tested for genetic expression of the PCA3 gene. If the sample is positive for PCA3, then the patient has a very high likelihood of having prostatic cancer.
PCA3Plus®, validated by Bostwick Laboratories®, predicts prostate cancer with a sensitivity of 95.7%.
Bostwick Laboratories® is an international reference laboratory that specializes in state-of-the-art testing. It focuses on urologic diseases such as prostate cancer.
PCA3Plus® has not been cleared or approved by the FDA, and is based upon reagents manufactured by Gen-Probe (San Diego, California). PCA3Plus® is a trademark of Bostwick Laboratories® uPM3™ is a trademark of DiagnoCure (Quebec City, Quebec, Canada).
Download the PCA3Plus® Brochure for more information
|